

November 24, 2020

**VIA REGULATIONS.GOV**

Division of Dockets Management (HFA-305)  
Food and Drug Administration  
Department of Health and Human Services  
5360 Fishers Lane, Room 1061  
Rockville, MD 20852

**RE: Withdrawal of Petition; Docket No. FDA-2020-P-1849**

Dear Sir or Madam:

This Petitioner hereby requests withdrawal of the above-referenced citizen petition requesting that FDA designate a new reference standard for hydrocortisone and neomycin sulfate and polymyxin B sulfate otic suspension/drops, 1%; Eq 3.5mg Base/mL; 10,000 Units/mL.

Sincerely yours,



David L. Rosen, B.S. Pharm., JD

Cc: Alvin Chi, J.D.  
Regulatory Counsel  
Center for Drug Evaluation and Research  
Office of Regulatory Policy  
[Sungjoon.Chi@fda.hhs.gov](mailto:Sungjoon.Chi@fda.hhs.gov)

AUSTIN  
BOSTON  
CHICAGO  
DALLAS  
DENVER

DETROIT  
HOUSTON  
JACKSONVILLE  
LOS ANGELES  
MADISON

MEXICO CITY  
MIAMI  
MILWAUKEE  
NEW YORK  
ORLANDO

SACRAMENTO  
SAN DIEGO  
SAN FRANCISCO  
SILICON VALLEY  
TALLAHASSEE

TAMPA  
WASHINGTON, D.C.  
BRUSSELS  
TOKYO